Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Marinus ( (MRNS) ) has issued an announcement.
Marinus Pharmaceuticals has terminated its agreements with Orion Corporation, including collaboration and supply agreements, as part of its strategic review. The termination includes a mutual release of claims, and Marinus will pay Orion €1.5 million under certain conditions, while Orion is relieved from a €500,000 payment previously due.
More about Marinus
Marinus Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapeutics. The company’s primary focus includes products incorporating ganaxolone, used for various medical indications.
YTD Price Performance: -96.59%
Average Trading Volume: 2,769,828
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $20.5M
See more data about MRNS stock on TipRanks’ Stock Analysis page.
